Pharma channel feed – Endpoints News

Pharma channel feed

Sanofi is jettisoning its infectious disease unit to Evotec — handing over cash, staff and a pipeline

8 years ago

Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star

8 years ago

Pfizer breaks off a 5-year, $635M collaboration deal with CytomX, with nothing to show for it

8 years ago

'Rigged' payment schemes by insurers and PBMs is blocking the switch to biosimilars, says FDA commissioner

8 years ago

Flanked by rivals and skeptics, Esperion flips positive data on first PhIII for a potentially game-changing cholesterol pill

8 years ago

Metavant makes a debut: Vivek Ramaswamy launches biotech #7 and builds a diabetes pipeline with Ligand deal

8 years ago

Made in China: TaiMed wins FDA OK for a 'breakthrough' HIV therapy for drug-resistant patients

8 years ago

Faster, more convenient Opdivo dosing schedules gives Bristol-Myers added edge in battle of the PD-1 blockbusters with Merck

8 years ago

After bagging Shire’s cell therapy castoff, Caladrius stock climbs

8 years ago

Cambridge star Magenta teams up with Heidelberg on bone marrow R&D pact that includes $334M in potential milestones

8 years ago

Stock flies high on Clearside’s PhIII macular edema trial results as drug improves vision

8 years ago

Celgene hands over $101M in cash to launch a research collaboration with protein player Vividion

8 years ago

Unum plays its first glimpse of human data in an $86M IPO, revealing two deaths and an FDA hold

8 years ago

Watch out Endo: Sorrento is after your $1B+ drug with FDA OK of ZTlido

8 years ago

Novartis wants to be a leader in a new generation of prescription digital med programs, pairs with Pear

8 years ago

It’s official: EMA to move into permanent Amsterdam premises in November ‘19 amid continued protests from Italy

8 years ago

J&J collaborates with Aldeyra on new drugs for systemic inflammatory diseases

8 years ago

Sovereign nonsense: Patent board joins the lineup of critics dissing Allergan's 'illusory' IP deal with the Mohawks

8 years ago

FDA provides a long-delayed OK for KemPharm’s opioid — with strings attached

8 years ago

The Trump effect: PwC report says the FDA has slammed the brakes on significant new drug regulations

8 years ago

Hit by an expected EMA rejection, Puma plans to appeal negative opinion on neratinib

8 years ago

Shionogi, Roche get their first approval for the next big thing in fighting the flu

8 years ago

Bristol-Myers axes 107 more staffers as it completes an R&D overhaul

8 years ago

Abandoned by J&J, faded hep C star Achillion axes staff and maps path to PhII readouts

8 years ago

First page Previous page 305 306 307308309 310 311 Next page Last page